Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500440 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Anoopjit Singh Kooner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA. Hauptthemen laut MEDLINE: Toxoplasma, Protein Kinase Inhibitors, Drug Design, Protein Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, Tg CDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to Tg CDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent Tg CDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
ORCID-Profile: Anoopjit Singh Kooner, Igi Vilza, Michael P Mannino, Shrushti Patil, James W Janetka
Förderung
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Kooner, A. S., Norman, M., Vilza, I., Mannino, M. P., Dhason, M. S., Helander, J., Patil, S., Sibley, L. D., & Janetka, J. W. (2025). Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202500440
Vancouver
Kooner AS, Norman M, Vilza I, Mannino MP, Dhason MS, Helander J, et al. Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors. ChemMedChem. 2025. doi:10.1002/cmdc.202500440
BibTeX
@article{Kooner2025,
author = {Kooner, Anoopjit Singh and Norman, Mariah and Vilza, Igi and Mannino, Michael P and Dhason, Mary Savari and Helander, Jon and Patil, Shrushti and Sibley, L David and Janetka, James W},
title = {Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500440}
}
EUVIMED